Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells

Published:2017-03 Issue: Volume:388 Page:262-268
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

González-Fernández Yolanda,Imbuluzqueta Edurne,Zalacain Marta,Mollinedo Faustino,Patiño-García Ana,Blanco-Prieto María J.

Funder

Asociación Española Contra el Cáncer

Fundación Caja Navarra

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Antitumoral-lipid-based nanoparticles: a platform for future application in osteosarcoma therapy;Gonzalez-Fernandez;Curr. Pharm. Des.,2015

2. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma;Jaffe;Adv. Exp. Med. Biol.,2014

3. Therapy for osteosarcoma: where do we go from here?;Chou;Paediatr. Drugs,2008

4. Doxorubicin, DNA torsion, and chromatin dynamics;Yang;Biochim. Biophys. Acta,2014

5. Osteosarcoma treatment – where do we stand? A state of the art review;Luetke;Cancer Treat. Rev.,2014

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current advance of nanotechnology in diagnosis and treatment for malignant tumors;Signal Transduction and Targeted Therapy;2024-08-12

2. Innovative Pharmaceutical Techniques for Paediatric Dosage Forms: A Systematic Review on 3D Printing, Prilling/Vibration and Microfluidic Platform;Journal of Pharmaceutical Sciences;2024-07

3. Correlation of High-Grade Osteosarcoma Response to Chemotherapy with Enhanced Tissue Immunological Response: Analysis of CD95R, IFN-γ, Catalase, Hsp70, and VEGF;Virchows Archiv;2024-05-15

4. Osteosarcoma-targeted Cu and Ce based oxide nanoplatform for NIR II fluorescence/magnetic resonance dual-mode imaging and ros cascade amplification along with immunotherapy;Journal of Nanobiotechnology;2024-04-04

5. Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells;Frontiers in Pharmacology;2024-02-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3